Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels.
Previously (L. C. Young et al., Clin. Cancer Res., 5: 673-680, 1999), we found, in a panel of 23 lung cancer cell lines that had not been selected for in vitro drug resistance, that the mRNA levels of MRP3 and MRP1, two members of the ATP-binding cassette superfamily of transport proteins, correlated with resistance to doxorubicin, vincristine, VP-16, and cis-diamminedicholoroplatinum(II). To extend these studies, we measured multidrug resistance protein (MRP)1, MRP2, and MRP3 protein levels in a panel of 30 lung cancer cell lines that included the original 23 cell lines as well as an additional 7 unselected lung cancer cell lines. In the case of MRP3, a polyclonal antibody was developed that was found to be a sensitive reagent for the detection of MRP3 by Western blot analysis. We found good agreement in the original 23 cell lines between the cognate mRNA and protein levels for MRP1, MRP2, and, especially, MRP3 (r, 0.852), supporting the use of semiquantitative PCR to predict MRP1, MRP2, and MRP3 protein levels in patient samples. There were also strong correlations between the mRNA and protein levels of MRP3 and MRP1, which suggested that these genes might be expressed in a coordinate manner. MRP3, MRP1, and MRP2 protein levels were higher in the non-small cell lung cancer (NSCLC) than in the SCLC cell lines and, in addition, MRP3 and MRP2 were detected almost exclusively in the NSCLC cell lines. Finally, we found that both MRP3 and MRP1, but not MRP2, protein levels correlated with decreased sensitivity of these lung cancer cell lines to doxorubicin, VCR, VP-16, and cis-diamminedicholoroplatinum(II). These findings are consistent with our hypothesis that both MRP3 and MRP1 are components of the multifactorial multidrug resistance phenotype of lung cancer and that MRP3 contributes to the intrinsic resistance of NSCLC cells.
Young
L C
LC
Department of Pathology, Queen's University, Kingston, Ontario, K7L 3N6 Canada.
Campling
B G
BG
Cole
S P
SP
Deeley
R G
RG
Gerlach
J H
JH
D000581:Amidohydrolases / Q000378:metabolism; D000970:Antineoplastic Agents / Q000494:pharmacology*; D015153:Blotting, Western; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000378:metabolism; D018288:Carcinoma, Small Cell / Q000188:drug therapy / Q000378:metabolism; D002462:Cell Membrane / Q000378:metabolism; D004268:DNA-Binding Proteins / Q000096:biosynthesis*; D051047:Dihydrolipoyllysine-Residue Acetyltransferase; D004591:Electrophoresis, Polyacrylamide Gel; D005656:Fungal Proteins / Q000096:biosynthesis*; D006801:Humans; D007074:Immunoglobulin G / Q000378:metabolism; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000378:metabolism*; D024101:Mitochondrial Proteins; D027425:ATP-Binding Cassette, Sub-Family C Proteins; D000074081:MutS Homolog 3 Protein; D043524:Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase; D010641:Phenotype; D016133:Polymerase Chain Reaction; D011768:Pyruvate Dehydrogenase Complex; D012333:RNA, Messenger / Q000378:metabolism*; D012269:Ribosomal Proteins / Q000096:biosynthesis*; D029701:Saccharomyces cerevisiae Proteins; D014407:Tumor Cells, Cultured
D000581:Amidohydrolases; D000970:Antineoplastic Agents; D004268:DNA-Binding Proteins; D051047:Dihydrolipoyllysine-Residue Acetyltransferase; D005656:Fungal Proteins; D007074:Immunoglobulin G; D024101:Mitochondrial Proteins; D027425:ATP-Binding Cassette, Sub-Family C Proteins; D000074081:MutS Homolog 3 Protein; D043524:Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase; D011768:Pyruvate Dehydrogenase Complex; D012333:RNA, Messenger; D012269:Ribosomal Proteins; D029701:Saccharomyces cerevisiae Proteins; C093947:MRP2 protein, S cerevisiae; C078444:MSH3 protein, human; C067358:MRP-3 protein, Neurospora crassa; C421109:multidrug resistance-associated protein 1